Japan: Takeda gets Japanese approval for US$62b Shire purchase

Takeda Pharmaceutical announced on Thursday, October 18, that Japan’s Fair Trade Commission had approved its US$62 billion acquisition of Shire, bringing the Japanese firm closer to sealing a deal that will make it a global top 10 drugmaker. The deal, which will be the largest overseas purchase by a Japanese company, has already received unconditional clearance from regulators in the United States, Brazil, and China.

“Takeda is proud of its Japanese heritage, and we are looking forward to building on this heritage as a combined company to continue delivering highly-innovative medicines that are transformative to patients in Japan and around the world,”Takeda CEO Christophe Weber said in a statement. Takeda is also waiting for a nod from EU antitrust regulatorsThey are expected to make a decision by November 6, but can open a four-month long investigation if they have serious concerns.

Full Content: Endpoints News

Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.


More Articles